MARKET

SAVA

SAVA

Cassava Sciences Inc
NASDAQ
23.00
+0.02
+0.09%
After Hours: 23.00 0 0.00% 19:59 03/01 EST
OPEN
23.00
PREV CLOSE
22.98
HIGH
23.28
LOW
22.81
VOLUME
381.58K
TURNOVER
0
52 WEEK HIGH
32.10
52 WEEK LOW
12.32
MARKET CAP
994.18M
P/E (TTM)
-10.0327
1D
5D
1M
3M
1Y
5Y
Cassava Sciences Inc: Annual report
Press release · 3d ago
Cassava Sciences: Q4 Earnings Insights
Cassava Sciences reported its Q4 earnings on February 28. Cassava Sciences beat estimates by 4.0%. The company's revenue was down $0 from the same period last year. The company is expected to report its earnings on Wednesday morning, February 28, 2024.
Benzinga · 3d ago
Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), Repare Therapeutics (RPTX)
TipRanks · 3d ago
Cassava Sciences GAAP EPS of -$0.50
Cassava Sciences GAAP EPS of -$0.50. $121.1 million in Cash and Cash Equivalents at December 31, 2023. $21.8 million to be raised in 2024 from exercise of Warrants. Cassava Sciences, Inc. (SAVA) stock.
Seeking Alpha · 4d ago
Cassava Sciences Q4 EPS $(0.50) Beats $(0.52) Estimate
Benzinga · 4d ago
Weekly Report: what happened at SAVA last week (0219-0223)?
Weekly Report · 6d ago
Weekly Report: what happened at SAVA last week (0212-0216)?
Weekly Report · 02/19 10:48
Brian's Big Idea on Low Priced Stocks
NASDAQ · 02/13 21:45
More
About SAVA
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in the detection and treatment of neurodegenerative diseases, such as Alzheimer’s disease. The Company develops pharmaceutical product candidates that offer improvements to patients and healthcare professionals. The Company has two biopharmaceutical assets under development, including its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer’s disease dementia, which is under Phase III clinical studies; and its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. Simufilam is a proprietary small molecule (oral) drug, which targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. SavaDx is designed as an antibody-based detection system for altered filamin A (FLNA).

Webull offers Cassava Sciences Inc stock information, including NASDAQ: SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.